Comparative effectiveness of the dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to central retinal vein occlusion

Ophthalmic Surg Lasers Imaging Retina. 2013 Jan-Feb;44(1):28-33. doi: 10.3928/23258160-20121221-09.

Abstract

Background and objective: To compare duration and efficacy of the dexamethasone (DEX) intravitreal implant in vitrectomized (pars plana vitrectomy [PPV] group) and non-vitrectomized eyes (control group) with macular edema related to central retinal vein occlusion (CRVO).

Patients and methods: Eyes that received the DEX implant for CRVO related to macular edema were included in a retrospective chart review. Outcomes measured were best-corrected visual acuity (BCVA) and central macular thickness (CMT).

Results: Fifteen eyes were included in the study. Eight of 15 eyes had prior vitrectomy. Mean BCVA was 20/160 in both groups. Baseline mean CMT was 550 μm (PPV group) and 556 μm (control group, P = .70), and improved to 307.5 μm (PPV group) and 316.3 μm (control group) (P = .90) after implant. The BCVA was 20/125 (PPV group) and 20/200 (control group) (P = .60). Time to next procedure was similar in both groups.

Conclusions: This retrospective study shows similar CMT reductions with DEX implant treatment for CRVO-related macular edema in vitrectomized and non-vitrectomized eyes.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Dexamethasone / administration & dosage*
  • Drug Implants
  • Female
  • Glucocorticoids / administration & dosage*
  • Humans
  • Macular Edema / drug therapy*
  • Macular Edema / etiology
  • Male
  • Middle Aged
  • Retina / pathology
  • Retinal Vein Occlusion / complications
  • Retinal Vein Occlusion / drug therapy
  • Retrospective Studies
  • Treatment Outcome
  • Visual Acuity / physiology
  • Vitrectomy*
  • Vitreous Body / drug effects*

Substances

  • Drug Implants
  • Glucocorticoids
  • Dexamethasone